Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 53Recruiting 26Terminated 19Unknown 8Active not recruiting 8Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 174Gastrointestinal 23Breast 22Genitourinary 11Gynecologic 9Head & Neck 8Dermatologic 7CNS 7Other solid neoplasm 3Endocrine 3Sarcoma 1Other neoplasm 1Other hematologic neoplasm 1Other 1NET 1Lymphoid 1

Conditions

Sarcoma 60Gliosarcoma 19Glioblastoma 19Osteosarcoma 15Lymphoma 14Central Nervous System Neoplasms 13Dendritic Cell Sarcoma, Interdigitating 11Rhabdomyosarcoma 10Oligodendroglioma 10Neuroblastoma 10Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Brain Neoplasms 10Bone Neoplasms 10Astrocytoma 10Recurrence 9Breast Neoplasms 9Sarcoma, Ewing 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 8Liposarcoma 8Glioma 8Burkitt Lymphoma 8Wilms Tumor 7Neoplasm Metastasis 7Melanoma 7Hodgkin Disease 7Gastrointestinal Stromal Tumors 7Ovarian Neoplasms 6Medulloblastoma 6

Interventions

Trabectedin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lung Neoplasms × Sarcoma × Clear all
NCT03496519 2018-10-09

Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

University of Colorado, Denver

Phase 1 Withdrawn
SarcomaThoracic

Lung Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡